文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

基于PSMA-PET/CT的前列腺癌患者放疗方案调整

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT.
PubMed 文献 · Radiat Oncol · 2022-01-29

这项回顾性先导研究纳入43例转诊至放疗科的前列腺癌患者,按初始计划分为根治性放疗、挽救性放疗和寡转移放疗三组。PSMA-PET/CT后60.5%(26/43)患者的初始放疗因新发现(转移和/或复发)而改变,仅39.5%(17/43)按原计划治疗。结果表明PSMA-PET/CT影响治疗决策及放疗和辅助治疗方案的选择。

要点

  • PSMA-PET/CT后60.5%(26/43)患者初始放疗计划因新发现转移和/或复发而改变。
  • 50%(16/32)患者的放疗计划因PSMA-PET/CT结果而改变。
  • 仅39.5%(17/43)患者按初始治疗计划接受治疗。

核心结论

  • PSMA-PET/CT影响前列腺癌管理中的治疗决策以及放疗和辅助治疗方案的选择。

研究设计与样本

  • 回顾性先导研究,纳入43例从前列腺癌患者转诊至放疗科接受放疗的患者,18F-PSMA-PET/CT主要由放疗科医生因缺乏近期影像分期而开具。
  • 患者按初始计划治疗分为三组:根治性放疗(新诊断前列腺癌)、挽救性放疗(根治性前列腺切除术后生化复发)、寡转移放疗(系统治疗后反应良好的寡转移前列腺癌)。

主要发现

  • PSMA-PET/CT后,60.5%(26/43)患者的初始计划放疗因新发现(转移和/或复发)而改变。
  • PSMA-PET/CT结果影响60.5%(26/43)患者的最终治疗选择,50%(16/32)患者的放疗计划因PSMA-PET/CT而改变。
  • 仅39.5%(17/43)接受PSMA-PET/CT的患者按初始治疗计划接受治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prostate cancer radiotherapy. METHODS: This retrospective pilot study included 43 prostate cancer (PCa) patients referred to our radiation oncologist department, from the urology department, for radiation therapy. 18F-PSMA-PET/CT was ordered by the radiation oncologists mainly due to the lack of resent image staging. The patients were divided into three different groups according to their initially planned treatments: radical radiation therapy (RT) (newly diagnosed PCa patients), salvage RT (patients with biochemical recurrence after radical prostatectomy), or oligometastatic RT (oligometastatic PCa patients with good response after systemic treatment). RESULTS: Following PSMA-PET/CT, the initially planned RT was changed for 60.5% of the patients due to new findings (metastases and/or recurrent disease). The final treatment choice was effected by PSMA-PET/CT outcome in 60.5% (26/43) of the patients, and in 50% (16/32) of patients, the radiation treatment plan changed following PSMA-PET/CT. Only 39.5% (17/43) of the patients who underwent PSMA-PET/CT were treated according to their initial treatment plans. CONCLUSIONS: Our results indicate that PSMA-PET/CT impacts treatment decisions and the selection of RT as well as adjuvant treatment protocols in the management of prostate cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Karagiannis V, Wichmann V, Saarinen J, et al. Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT. Radiat Oncol. 2022. PMID: 35093103. doi:10.1186/s13014-022-01989-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。